Secukinumab Receives 2 New Approvals: PsA & AS

Secukinumab (Cosentyx) is to be used under the guidance and supervision of a physician. When deemed appropriate after proper training in subcutaneously injection technique, patients may self-administer using the Sensoready pen or prefilled syringe. The lyophilized powder is for healthcare provider use only. The drug should be administered at a different anatomic location (such as upper arms, thighs or any quadrant of the abdomen) than the previous injection and not into areas where the skin is tender, bruised, erythematous, indurated or affected by psoriasis.

Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

1. Novartis receives two new FDA approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis in the US. Novartis press release. 2016 Jan 15.
2. Cosentyx (secukinumab) product labeling. Novartis. Updated January 2016.